Horizon Europe’s Cluster 1 – Health focuses on improving and protecting the health and well-being of people of all ages, by generating new knowledge, developing innovative solutions and integrating where relevant a gender perspective to prevent, diagnose, monitor, treat and cure diseases.
Further aims include developing health technologies, mitigating health risks, protecting populations and promoting good health and well-being in general and at work.
Finally, this cluster also aims to make public health systems more cost-effective, equitable and sustainable, prevent and tackle poverty-related diseases and support and enable patients’ participation and self-management.
🗂️ Discover the full range of funding opportunities in the 2026-2027 Work Programme:
Horizon Europe Work Programme 2026-2027 – Health
Call: Partnerships in Health (2026/1)
📅 Deadline for submissions: 15 Sept 2026
The total indicative budget for this topic is about €91M.
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
- The EU is reinforced as an internationally recognised driver of research and innovation in Rare Diseases (RD) and thereby substantially contributing to the achievement of the Sustainable Development Goals related to rare diseases.
- Research funders align, adopt and implement their RD research policies allowing for the optimal generation and translation of knowledge into meaningful health products and interventions responding to the needs of people living with a rare disease across Europe and globally.
- The RD research community at large benefit from and use an improved comprehensive knowledge framework and cross-border FAIR191 data access and analysis, including rare diseases registries, by integrating the EU, national/regional data and information infrastructures to improve translational research.
- People living with a rare disease, including those from underrepresented communities, benefit from a more timely, equitable access to innovative, sustainable and high-quality healthcare including novel diagnosis and treatments, taking stock of highly integrated research and healthcare systems.
- Researchers, innovators -as well as people living with a rare disease and their advocates (as co-creators)- effectively constitute and operate into an integrated research and innovation ecosystem to deliver cost-effective diagnosis and treatments.
- Public and private actors, including civil society (e.g. Non-Governmental Organisations, charities), establish coordinated and efficient multi-stakeholder collaborations at EU and national (including regional) levels, allowing for more effective clinical research, for example aiming at improved success rates of therapeutic development.
For more detailed info, please visit the EU Funding & Tender Portal.
